Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

8.83

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

-0.01

EPS Last/This Y

0.35

EPS This/Next Y

0.14

Price

1.07

Target Price

5.36

Analyst Recom

2.36

Performance Q

-13.71

Relative Volume

0.43

Beta

2.24

Ticker: FATE



21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04FATE1.130.0710.006424
2025-07-07FATE1.0650.070.006425
2025-07-08FATE1.090.071.846439
2025-07-09FATE1.1450.080.006578
2025-07-10FATE1.160.080.006785
2025-07-11FATE1.1450.080.007134
2025-07-14FATE1.1450.080.007093
2025-07-15FATE1.140.070.007498
2025-07-16FATE1.130.070.007595
2025-07-17FATE1.1550.070.007594
2025-07-18FATE1.1350.070.027806
2025-07-21FATE1.1450.070.006205
2025-07-22FATE1.240.070.006281
2025-07-23FATE1.270.070.116169
2025-07-24FATE1.2450.070.036468
2025-07-25FATE1.2350.070.626450
2025-07-28FATE1.3050.080.006545
2025-07-29FATE1.160.080.296629
2025-07-30FATE1.1350.080.006632
2025-07-31FATE1.10.080.006739
2025-08-01FATE1.0650.080.006731
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1



21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04FATE1.12-1.4- -1.24
2025-07-07FATE1.07-1.4- -1.24
2025-07-08FATE1.09-1.4- -1.24
2025-07-09FATE1.15-1.4- -1.24
2025-07-10FATE1.16-1.4- -1.24
2025-07-11FATE1.15-1.4- -1.24
2025-07-14FATE1.15-1.4- -1.24
2025-07-15FATE1.13-1.4- -1.24
2025-07-16FATE1.13-1.4- -1.24
2025-07-17FATE1.15-1.4- -1.24
2025-07-18FATE1.14-1.4- -1.24
2025-07-21FATE1.15-1.4- -1.24
2025-07-22FATE1.24-1.4- -1.24
2025-07-23FATE1.28-1.4- -1.24
2025-07-24FATE1.25-1.4- -1.24
2025-07-25FATE1.24-1.4- -1.24
2025-07-28FATE1.30-1.4- -1.24
2025-07-29FATE1.17-1.4- -1.24
2025-07-30FATE1.14-1.4- -1.24
2025-07-31FATE1.10-1.4- -1.24
2025-08-01FATE1.07-4.3- -1.29
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04FATE-0.27-6.168.88
2025-07-07FATE-0.27-6.178.88
2025-07-08FATE-0.27-6.178.88
2025-07-09FATE-0.27-6.178.88
2025-07-10FATE-0.27-6.178.88
2025-07-11FATE-0.27-6.178.91
2025-07-14FATE0.00-6.148.91
2025-07-15FATE0.00-6.148.91
2025-07-16FATE0.00-6.148.91
2025-07-17FATE0.00-6.148.91
2025-07-18FATE0.00-6.148.91
2025-07-21FATE0.00-6.368.91
2025-07-22FATE0.00-6.368.91
2025-07-23FATE0.00-6.368.91
2025-07-24FATE0.00-6.368.91
2025-07-25FATE0.00-6.368.83
2025-07-28FATE0.00-6.038.83
2025-07-29FATE0.00-6.038.83
2025-07-30FATE0.00-6.038.83
2025-07-31FATE0.00-6.038.83
2025-08-01FATE0.00-6.038.83
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.32

Avg. EPS Est. Current Quarter

-0.33

Avg. EPS Est. Next Quarter

-0.33

Insider Transactions

Institutional Transactions

-6.03

Beta

2.24

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

15

Growth Score

28

Sentiment Score

1

Actual DrawDown %

99.1

Max Drawdown 5-Year %

-99.4

Target Price

5.36

P/E

Forward P/E

PEG

P/S

9.19

P/B

0.43

P/Free Cash Flow

EPS

-1.49

Average EPS Est. Cur. Y​

-1.29

EPS Next Y. (Est.)

-1.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1318.93

Relative Volume

0.43

Return on Equity vs Sector %

-84.7

Return on Equity vs Industry %

-66.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

Fate Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About